Benjamin Hohl - 27 Mar 2025 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
31 Mar 2025, 19:37:34 UTC
Prior SEC filing
26 Mar 2025
Next SEC filing
30 Apr 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Benjamin Hohl
Filing notes and source

Key filing fact

Benjamin Hohl filed Form 4 for Enliven Therapeutics, Inc. (ELVN) on 31 Mar 2025.

Key facts

  • This page summarizes Benjamin Hohl's Form 4 filing for Enliven Therapeutics, Inc. (ELVN).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 31 Mar 2025, 19:37.

Change

  • Previous filing in this sequence was filed on 26 Mar 2025.
  • Current net transaction value: -$61,261.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ELVN transaction

Common Stock

Options Exercise

Transaction value
$8,060
Shares
+3,250
Change %
+14%
Price
$2.48
Shares after
26,250
Date
27 Mar 2025
Ownership
Direct
Footnotes
F1
ELVN transaction

Common Stock

Sale

Transaction value
-$69,321
Shares
-3,250
Change %
-12%
Price
$21.33
Shares after
23,000
Date
27 Mar 2025
Ownership
Direct
Footnotes
F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELVN transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value
$0
Shares
-3,250
Change %
-2.5%
Price
$0.000000
Shares after
128,556
Date
27 Mar 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
3,250
Exercise price
$2.48
Footnotes
F1, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.

Footnote F2

This transaction was executed in multiple trades at prices ranging from $20.75 to $21.645. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Footnote F3

The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .